DelveInsight Business Research LLP

DelveInsight’s “Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Irritable Bowel Syndrome (IBS), historical and forecasted epidemiology as well as the Irritable Bowel Syndrome (IBS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Irritable Bowel Syndrome (IBS) market report provides current treatment practices, emerging drugs, Irritable Bowel Syndrome (IBS) market share of the individual therapies, current and forecasted Irritable Bowel Syndrome (IBS) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Irritable Bowel Syndrome (IBS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Irritable Bowel Syndrome (IBS) market.

Key benefits of the Irritable Bowel Syndrome Market report:

• The report covers the descriptive overview of Irritable Bowel Syndrome (IBS), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies

• Comprehensive insight has been provided into the Irritable Bowel Syndrome (IBS) epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Irritable Bowel Syndrome (IBS) is provided, along with the assessment of new therapies which will have an impact on the current treatment landscape

• A detailed review of the Irritable Bowel Syndrome (IBS) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Irritable Bowel Syndrome (IBS) market

 Got queries? Click here to know more about the Irritable Bowel Syndrome Market Landscape 

Irritable Bowel Syndrome Overview

Irritable bowel syndrome (IBS) is one of the most commonly diagnosed gastrointestinal diseases. IBS, in the absence of any other causative disease, is defined as the presence of abdominal pain or discomfort with altered bowel habits. The etiology of Irritable bowel syndrome (IBS) or IBS is broad and not clearly understood. However, the pathophysiology of IBS is broad and includes abnormalities involving motility, visceral sensation, brain-gut interaction, and psychosocial distress.

IBS typically consists of abdominal pain or discomfort, altered bowel habits along with either constipation, diarrhea or both. Other complaints in patients with IBS include bloating, distention, symptoms brought on by food intake, and a change in pain location, and stool pattern with time. IBS has a good prognosis, and the diagnosis is unlikely to change on follow-up. Diagnosis of IBS has evolved since its first discovery, and today the Rome IV diagnostic criteria (The Rome IV consensus is a robust standard for a clinical and research approach to functional gastrointestinal disorders) is used to diagnose IBS. 

Irritable Bowel Syndrome Epidemiological Insights:

• Irritable bowel syndrome (IBS) can be a very disabling syndrome for patients, and it has been shown to be a very common reason for seeking medical attention. Nearly 12% of patients seek medical care in primary care practices for IBS-related complaints. Studies have demonstrated that the prevalence of IBS ranges between 10-15%. However, the majority of these patients do not seek medical care.

• In the United States, IBS symptoms are 1.5 to 2 times more prevalent among women than men. Moreover, women are more likely to report abdominal pain and constipation, whereas men are more likely to report diarrhea.IBS can be broken down into more specific diagnoses, which include IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed bowel patterns (IBS-M). The prevalence of these three diagnoses differs in the United States versus Europe. In the United States, there is an equal distribution of these diagnoses, whereas in Europe IBS-C or IBS-M can be more prevalent.The prevalence of IBS decreases with age, suggesting that symptoms remit over time.

Irritable Bowel Syndrome Epidemiological Segmentation

• Irritable Bowel Syndrome is prevalent population

• Irritable Bowel Syndrome diagnosed with prevalent cases 

• Irritable Bowel Syndrome sub type-specific, prevalent cases 

• Irritable Bowel Syndrome gender specific prevalent cases 

• Irritable Bowel Syndrome age-specific prevalent cases 

Irritable Bowel Syndrome Market Outlook 

The Irritable Bowel Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Irritable Bowel Syndrome market trends by analyzing the impact of current Irritable Bowel Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Irritable Bowel Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Irritable Bowel Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Irritable Bowel Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.

 Learn more by requesting for sample @ Irritable Bowel Syndrome Market Landscape

 Irritable Bowel Syndrome Key Companies  

• OrphoMed, Inc

• D pharma

And many others 

Irritable Bowel Syndrome Key Therapies 

• ORP-101

• Blautix

• And many others 

 Table of Contents

1. Key Insights 

2. Report Introduction 

3. Executive Summary of Irritable Bowel Syndrome Market 

4. Disease Background and Overview

5. Epidemiology and patient population

6. The United States 

7. EU 5

8. Irritable Bowel Syndrome Market  Emerging Therapies

9. Irritable Bowel Syndrome Market Outlook

10.  Market Access and Reimbursement of Therapies

11.  Appendix

12. Irritable Bowel Syndrome  Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

Click here to read more about the Irritable Bowel Syndrome Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services